ArticleMarine biotechnology (New York, N.Y.)2024
Chnoospora minima: a Robust Candidate for Hyperglycemia Management, Unveiling Potent Inhibitory Compounds and Their Therapeutic Potential.
Article in Marine biotechnology (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The present study aimed to isolate a bioactive compound from Sri Lankan edible marine brown algae, Chnoospora minima, to manage diabetes. The de-polysaccharide crude methanolic extract was partitioned using hexane, chloroform, and ethyl acetate with increased polarity. The samples were subjected to determine the quantitative phytochemical analysis, antioxidants, and antidiabetic potentials. Further, the potent antidiabetic fraction was selected to isolate an active compound using bioactivity-guided fractionation. From the selected extract, the chloroform fraction exhibited comparatively high TPC (59.01 ± 1.86 mg GAE/g), TFC (5.14 ± 0.43 mg QE/g) and alkaloid content (2.79 ± 0.31 PE/g of extract). Crude methanol extract exhibited a potent DPPH activity (IC
Indexed as
Identifiers
39259314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.